Saturday, December 3, 2022


Biotechnology News Magazine

Schreiner MediPharm & SCHOTT Pharma Debut Prefilled Syringes with RFID-Labels

Latest Posts

Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 1 Study of Bomedemstat in Combination with Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia

Venetoclax is a BCL-2 inhibitor approved by the U.S. Food and Drug Administration (FDA) for treatment of several hematologic cancers, including in combination with azacytidine for elderly patients with AML unable to tolerate the standard of care.

Acer Therapeutics Announces $1.5M Private Placement

The proceeds from the private placement will be used by Acer Therapeutics for working capital and general corporate purposes and, together with Acer’s existing cash and cash equivalents, are expected to be sufficient to fund the Company’s anticipated operating and capital requirements through the fourth quarter of 2022.

AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “The selection of ACI-35.030 for further development is a significant step for this collaboration. Early clinical testing showed that ACI-35.030 was generally well tolerated and induced specific activity against the pathological species of Tau, including the neurotoxic pTau and enriched paired helical filaments (ePHF) species, both of which are closely implicated in Alzheimer’s disease (AD).

TransCode Therapeutics Announces eIND Submission to US FDA for Planned First-in-Human Clinical Trial in Patients with Advanced Solid Tumors

The planned clinical trial is to evaluate TransCode’s lead therapeutic candidate, TTX-MC138, in cancer patients with advanced solid tumors. ​TTX-MC138 is designed to inhibit the pro-metastatic RNA, microRNA-10b, described as the master regulator of metastasis in a number of advanced solid tumors. TransCode Therapeutics believes that TTX-MC138 could be used as a treatment for many of these cancers.

Schreiner MediPharm, a Germany-based global provider of innovative functional label solutions for the healthcare industry, has partnered with SCHOTT Pharma, a specialist in drug containment and delivery solutions for medications, to develop a solution to equip prefilled syringes with RFID. Among other applications, the combination syringe and smart label opens up broad opportunities to optimize hospital routines. The solution premiered at the recent PDA Universe of Pre-Filled Syringes and Injection Devices Conference, in California.

Previously, the ongoing partnership between Schreiner MediPharm and SCHOTT Pharma had been focused primarily on equipping COC syringes with analog functional labels. With this latest effort, the two pharmaceutical packaging experts are digitizing prefilled syringes. What differentiates the new RFID-Labels is the combination of conventional product information marking and the application of unique, digital identifiers for each unit. This enables optimized processes in hospital inventory management, patient care and documentation, as well as the digitial identification of medications and medical devices. In addition, digital first-opening indication to protect the integrity of the syringe can be incorporated.

To successfully implement this innovation – and to ensure reliable RFID functionality pertaining to performance and range – various characteristics of the prefilled syringe must be considered. Aside from materials such as COC, PP, or glass, each of which can affect range and trouble-free reading of the tag, syringe size and diameter play a key role: The smaller the syringe, the less space for product marking and integration of the RFID chip. Plus, smaller tags typically yield shorter read ranges. In addition, syringe curvature may affect performance, especially in the case of small diameters.

The dielectric properties of the medications contained in the syringe also play a role. In particular, water-based active ingredients can have a negative impact on a tag’s radio transmission performance. This requires precise positioning of the RFID-Label and integrated inlay according to the liquid and fill level. Additionally, special data standards for identification and unit-level tracking – such as UnitVisID or GS1, which enable all relevant stakeholders to interpret and use the data – must be considered, as well as integration in the respective infrastructure.

Schreiner MediPharm and SCHOTT Pharma can adapt the solution to a customer’s specific requirements, to ensure optimal functionality from production to final use. This helps enhance product safety and avoid potential medication errors.

The new solution from Schreiner MediPharm and SCHOTT Pharma was presented for the first time at the PDA Universe of Pre-filled Syringes and Injection Devices Conference, October 18-19 in Palm Springs, CA. At the event, Arne Rehm, Senior Product Manager RFID/NFC Solutions at Schreiner MediPharm, and Tom van Ginneken, Head of Global Product Management for SCHOTT TOPPAC®, delivered a joint presentation under the motto “Making Pre-filled Syringes Smart.”

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine